Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197240 | 0.85 | ACHE (0.60) | ACHEFGFR1FGFR2FGFR3MAOA | |
| SCHEMBL21018063 | 0.85 | ACHE (0.82) | ACHEFGFR1RUNX1LTA4HPDGFRB | |
| SCHEMBL28426065 | 0.82 | HRH4 (0.62) | ACHEFGFR1FGFR2FGFR3NPC1 | |
| SCHEMBL29992512 | 0.82 | MAOA (0.55) | ACHEFGFR1MAOALTA4HPDGFRB | |
| SCHEMBL14224666 | 0.81 | ACHE (0.51) | ACHEFGFR1FGFR2FGFR3RUNX1 | |
| SCHEMBL3380635 | 0.81 | ACHE (0.55) | ACHEFGFR1FGFR2FGFR3MAOA | |
| SCHEMBL8265310 | 0.79 | LTA4H (0.57) | ACHELTA4HPDGFRBKDRNPC1 | |
| SCHEMBL7401032 | 0.79 | TMEM97 (0.60) | ACHEKDM4EMEN1KMT2A | |
| SCHEMBL13460615 | 0.78 | PDGFRB (0.63) | ACHEMAOALTA4HPDGFRBKDR | |
| Hydrochloric Acid SCHEMBL31070034 | 0.77 | MAOA (0.69) | MAOALTA4HPDGFRBNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | ACHE 634/4885FGFR1 4274/4885FGFR2 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.